oral semaglutide approval Novo Nordisk's Wegovy® pill (oral 25 mg, once daily) has just been approved by the US FDA as the first GLP‑1 receptor agonist for long‑term weight management and CV risk Wegovy pill: With FDA approval,

In November 2024, Ms S was started on semaglutide 0.25 mg weekly for obesity by her internist

Unexpectedly, we found other new adverse reaction signals related to the gallbladder that were not mentioned in the specification, including cholecystitis acute (IC025 = 3.36) and cholecystitis chronic (IC025 = 3.13), both of which exhibited greater signal intensity than cholelithiasis (IC025 = 2.81)

This article does not claim that any reader will qualify for treatment through altRx

GLP-1 medications contain a synthetic version of this naturally occurring hormone that enhances its effects in the body

We manage insurance verification, support authorization, and ongoing care coordination, empowering you to remain focused on your health pursuits

Ther.: Nucleic Acids 35 , 113 (2024)